Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their revenue from selling products overseas. Because they're purchased in local currencies, the strong dollar is depressing the sales' value.
↧
